Merck expands partnership with Zymeworks for multispecific antibodies

Aside from Merck, Zymeworks has inked deals with a number of major pharma companies, including Eli Lilly, Celgene, GlaxoSmithKline and Daiichi Sankyo.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... Trastuzumab deruxtecan is central

Cortellis Drugs to Watch in 2020 report

10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]